Prospective observational study to monitor and assess the safety of Onpattro® patisiran-LNP in a real-world cohort of hATTR amyloidosis patientsFirst published 02/04/2021 Last updated 07/05/2025 EU PAS number: EUPAS40417StudyOngoing